Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
News: Translational Research and Interventional Oncology Research Program
Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.
A new study by W. Kimryn Rathmell, MD, PhD, and colleagues, reveals a gene mutation’s role in Von Hippel-Lindau syndrome, a genetically inherited disease which causes tumor growth in several organs.
Christine Lovly, MD, PhD, assistant professor of Medicine, has received a $200,000 grant to support promising new research on lung cancer.
Ronald Alvarez, MD, chair of the Department of Obstetrics and Gynecology, has formed the HPV-Associated Cancer Consortium Vanderbilt (HPVACTIVE) program to raise awareness and provide community-wide education about HPV-associated cancers.
A new study by Dai Chung, MD, and colleagues reports that a protein, called SIRT6, plays an important role in the growth of neuroblastoma and suggests that SIRT6 may be a target for new therapeutics for the disease.
Vanderbilt University Medical Center’s (VUMC) Lung Screening Program for patients at high risk for cancer recently reached a milestone, enrolling more than 700 patients and performing more than 1,000 CT screening examinations.
W. Kimryn Rathmell, MD, PhD, Cornelius A. Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt University Medical Center (VUMC), has been elected to the nominating committee of the American Society of Clinical Oncology (ASCO).
Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC)
Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.